47% of cancer overall positive response to treatment thanks to OncoDEEP combined tumour molecular profiling

PHARMACOGENOMIC TESTING TO GUIDE PERSONALIZED CANCER MEDICINE DECISIONS IN PRIVATE ONCOLOGY PRACTICE: A CASE STUDY

Astras G. et al Front. Oncol., 28 April 2020

DOWNLOAD FULL ARTICLE HERE

ABSTRACT

Innovative tumor profiling methodologies are utilized to elucidate the pharmacogenomic landscape of tumor cells in order to support the molecularly guided delivery of therapeutics. Indeed, improved clinical outcomes are achieved in oncology practice by providing the physicians with expert-guided, standardized, and easily interpretable knowledge, translated from molecular profiling analysis to support clinical decision-making. However, there is still limited utilization of the technology especially in small private oncology practices. In this work, we analyzed how molecularly guided interventions in 17 consented cancer patients led to an overall improvement of disease response rates in a private oncology center.

The precision medicine strategy was based on the OncoDEEP™ profiling solutions and focused on finding clinically actionable relationships between tumor biomarkers and drug responses. The obtained data support the notion that

(a) following the pharmacogenomic-derived recommendations favorably impacted cancer therapy progression, and

(b) the earlier profiling followed by the delivery of molecularly targeted therapy led to more durable and improved pharmacological response rates.

Moreover, we report the example of a patient with metastatic gastric adenocarcinoma who, based on the molecular profiling data, received an off-label therapy that resulted in a complete response and a current cancer-free maintenance status. Overall, our data provide a paradigm on how molecular tumor profiling can improve decision-making in the routine private oncology practice.

You may also be interested in these resources

Scientific Application Note

PANCREATIC CANCER: Addition of a PARP inhibitor (veliparib) to gemcitabine + cisplatin chemo did not improve outcomes for patients harbouring germline mutations in BRCA1/2 or PALB2

Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation Journal of Clinical Oncology May 01, 2020 ABSTRACT PURPOSEFive percent to 9% of pancreatic ductal...

Share This